PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24901052-4	2014	The combination of mitomycin C and rapamycin inactivated p70 S6 ribosomal kinase (S6K1) and dephosphorylated Bad, leading to dissociation of Bcl-xL from Bak, which resulted in Bak oligomerization, mitochondria dysfunction and cytochrome c release.	Sirolimus	35-44	BCL2 like 1	Homo sapiens	141-147	
23902659-7	2014	In the blastocyst embryos, anti-apoptotic Bcl-xL transcript levels were elevated in the 1nM rapamycin-treated group, whereas pro-apoptotic Bax transcript levels were decreased.	Sirolimus	92-101	BCL2 like 1	Homo sapiens	42-48	
18789402-0	2008	Rapamycin reverses TLR4 signaling-triggered tumor apoptosis resistance by disrupting Akt-mediated Bcl-xL upregulation.	Sirolimus	0-9	BCL2 like 1	Homo sapiens	98-104	
22190165-11	2012	Sorafenib/rapamycin combination resulted in downregulation of pAkt, pmTOR, p-p70S6K, p4EBP1, pGSK3beta, Mcl1, and Bcl-Xl.	Sirolimus	10-19	BCL2 like 1	Homo sapiens	114-120	
18789402-6	2008	Therefore, rapamycin may abrogate TLR4-triggered tumor apoptosis resistance by inhibiting Akt/NF-kappaB pathways and Bcl-xL expression, providing experimental evidence for the anti-tumor effect of rapamycin.	Sirolimus	11-20	BCL2 like 1	Homo sapiens	117-123	
18789402-6	2008	Therefore, rapamycin may abrogate TLR4-triggered tumor apoptosis resistance by inhibiting Akt/NF-kappaB pathways and Bcl-xL expression, providing experimental evidence for the anti-tumor effect of rapamycin.	Sirolimus	197-206	BCL2 like 1	Homo sapiens	117-123	
15782132-0	2005	Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax : Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity.	Sirolimus	0-9	BCL2 like 1	Homo sapiens	72-78	
17331842-9	2007	CONCLUSION: Rapamycin has significant anti-proliferation effect by induction of apoptosis via activation of caspase-3 and disruption of mitochondrial membrane potential, as well as by down-regulation of anti-apoptotic protein Bcl-2 and up-regulation of pro-apoptotic protein Bcl-xl on hepatocellular carcinoma cells.	Sirolimus	12-21	BCL2 like 1	Homo sapiens	275-281	
15782132-4	2005	Rapamycin induced apoptosis by increasing the Bax : Bcl-xL ratio as a consequence of the concomitant downregulation of Bcl-xL and upregulation of Bax, both at the post-transcriptional level.	Sirolimus	0-9	BCL2 like 1	Homo sapiens	52-58	
15782132-4	2005	Rapamycin induced apoptosis by increasing the Bax : Bcl-xL ratio as a consequence of the concomitant downregulation of Bcl-xL and upregulation of Bax, both at the post-transcriptional level.	Sirolimus	0-9	BCL2 like 1	Homo sapiens	119-125	
15782132-6	2005	Transient transfection studies using kinase-dead and rapamycin-resistant forms of mTOR demonstrated that only the downregulation of Bcl-xL was caused by the mTOR inhibitory action of rapamycin, which prevented cap-dependent translation initiation, whereas Bax upregulation was induced by rapamycin through a mechanism independent of its mTOR inhibitory activity.	Sirolimus	53-62	BCL2 like 1	Homo sapiens	132-138	
15782132-6	2005	Transient transfection studies using kinase-dead and rapamycin-resistant forms of mTOR demonstrated that only the downregulation of Bcl-xL was caused by the mTOR inhibitory action of rapamycin, which prevented cap-dependent translation initiation, whereas Bax upregulation was induced by rapamycin through a mechanism independent of its mTOR inhibitory activity.	Sirolimus	183-192	BCL2 like 1	Homo sapiens	132-138	
15505422-6	2004	Bcl-2/bclxL-specific antisense oligonucleotides restored the sensitivity of SK-OV-3 cells to apoptosis induction by rapamycin and RAD001.	Sirolimus	116-125	BCL2 like 1	Homo sapiens	6-11	
32062191-3	2020	Here we found that rapamycin inhibited human soluble BAFF (hsBAFF)-stimulated cell proliferation by inducing G1-cell cycle arrest, which was through downregulating the protein levels of CDK2, CDK4, CDK6, cyclin A, cyclin D1, and cyclin E. Rapamycin reduced hsBAFF-stimulated cell survival by downregulating the levels of anti-apoptotic proteins (Mcl-1, Bcl-2, Bcl-xL and survivin) and meanwhile upregulating the levels of pro-apoptotic proteins (BAK and BAX).	Sirolimus	19-28	BCL2 like 1	Homo sapiens	360-366	
31963866-9	2020	Activation of autophagy with autophagy inducer rapamycin also inhibited ROS-induced cell death and decreased proapoptotic proteins but increased antiapoptotic protein Bcl-XL, NF-kappaB, and Nrf2.	Sirolimus	47-56	BCL2 like 1	Homo sapiens	167-173	
31648572-7	2020	Abbreviations AKT protein kinase B ARMS alveolar rhabdomyosarcoma ATM ataxia telangiectasia mutated Bax Bcl-2-associated X protein Bcl-2 B-cell lymphoma 2 CDC2 cyclin-dependent kinase 2 Bcl-xL B-cell lymphoma-extra large c-FLIP cellular FLICE-like inhibitory protein CDDP cisplatin COX-2 cyclooxygenase-2 cyt c cytochrome c DNA-PKcs DNA-dependent protein kinase EGFR epidermal growth factor receptor EMT epithelial-mesenchymal transition ERK extracellular signal-regulated kinase ES Ewing`s sarcoma ETS2 erythroblastosis virus transcription factor 2 GBM glioblastoma multiforme HCC hepatocellular carcinoma HNSCC head and neck squamous cell carcinoma IAP inhibitor of apoptosis protein IkappaBalpha inhibitor of kappaB alpha IKK inhibitor of kappaB kinase IR ionizing radiation lncRNA long non-coding RNA luc luciferase Mcl-1 myeloid cell leukemia-1 MDR1 multidrug resistance protein 1 miR microRNA MMP-9 matrix metalloproteinase-9 mTOR mammalian target of rapamycin NB neuroblastoma NF-kappaB nuclear factor-kappaB NPC nasopharyngeal carcinoma NSCLC non-small cell lung cancer OSCC oral squamous cell carcinoma PARP poly-(ADP-ribose)-polymerase pH2AX phosphorylated histone 2AX-immunoreactive PI3K phosphatidylinositol 3-kinase Prp4K Pre-mRNA processing factor 4 kinase RCC renal cell carcinoma ROS reactive oxygen species SCC squamous cell carcinoma SLN solid lipid nanoparticle SOD2 superoxide dismutase 2 TERT telomerase reverse transcriptase TNF-alpha tumor necrosis factor-alpha TxnRd1 thioredoxin reductase-1 VEGF vascular endothelial growth factor XIAP X-linked inhibitor of apoptosis protein DeltaPsim mitochondrial membrane potential.	Sirolimus	957-966	BCL2 like 1	Homo sapiens	186-192	
25780003-2	2015	METHODS: NMSC and peritumoral epidermis protein expression of Bcl-xL and Mcl-1 were assessed by immunohistochemistry in renal transplant recipients receiving tacrolimus or sirolimus and the general population not receiving immunosuppression.	Sirolimus	172-181	BCL2 like 1	Homo sapiens	62-68